News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You might find this interesting:
CTHP
|
Followers
|
9
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
324
|
|
Created
|
06/09/09
|
Type
|
Free
|
| Moderators | |||
Cancer Therapeutics, Inc. is a biotechnology business incubator, with a specific emphasis on disruptive treatments and nanotechnology. It seeks out disruptive cancer research and technology opportunities to invest in, develop, and commercialize. The end result will be therapies, treatments, and pharmaceuticals targeted at more efficiently and effectively attacking cancer. CTI seeks partners to co-develop drugs in various stages in our pipeline.
CTI’s first investment under this strategy is NanoTherapies LLC. Nano’s products introduce disruptive technology into the treatment and detection of cancer through the use of calcium phosphate nanoparticles. These particles, about 350 times smaller than a human cell, provide both a safe and effective way to transport drugs and imaging materials into diseased cells. The compatibility of the calcium phosphate nanoparticle with the biomechanics of the human body makes it unique for application in the treatment of diseases. Patient benefits from drugs jacketed with calcium phosphate nanoparticles are immense.
The development of these life-changing therapies for cancer treatment is achieved through an evolving set of intellectual properties and patents derived from the exploitation of calcium phosphate nanoparticles for therapeutic and diagnostic applications. NanoTherapies has sole license and patent protection for the fundamental use of calcium phosphate nanoparticles in medical applications for the treatment and detection of blood cancers (all forms of leukemia). Nano also owns all rights to manufacturing technologies and patents required to produce pharmaceutical quality drugs at the scale and yield needed for commercial viability.
Four drugs have been identified for accelerated market delivery and early revenue: Methotrexate, Cytarabine, Fludarabine and Daunorubicin. Cerimide-based drugs and a newly discovered Amplified Photon Emission Therapy (APET) also comprise part of the product portfolio, but will require longer clinical trials to get to market.
Cancer Therapeutics, Inc. is a biotechnology business incubator, with a specific emphasis on disruptive treatments and nanotechnology. It seeks out disruptive cancer research and technology opportunities to invest in, develop, and commercialize. The end result will be therapies, treatments, and pharmaceuticals targeted at more efficiently and effectively attacking cancer. CTI seeks partners to co-develop drugs in various stages in our pipeline.
CTI’s first investment under this strategy is NanoTherapies LLC. Nano’s products introduce disruptive technology into the treatment and detection of cancer through the use of calcium phosphate nanoparticles. These particles, about 350 times smaller than a human cell, provide both a safe and effective way to transport drugs and imaging materials into diseased cells. The compatibility of the calcium phosphate nanoparticle with the biomechanics of the human body makes it unique for application in the treatment of diseases. Patient benefits from drugs jacketed with calcium phosphate nanoparticles are immense.
The development of these life-changing therapies for cancer treatment is achieved through an evolving set of intellectual properties and patents derived from the exploitation of calcium phosphate nanoparticles for therapeutic and diagnostic applications. NanoTherapies has sole license and patent protection for the fundamental use of calcium phosphate nanoparticles in medical applications for the treatment and detection of blood cancers (all forms of leukemia). Nano also owns all rights to manufacturing technologies and patents required to produce pharmaceutical quality drugs at the scale and yield needed for commercial viability.
Four drugs have been identified for accelerated market delivery and early revenue: Methotrexate, Cytarabine, Fludarabine and Daunorubicin. Cerimide-based drugs and a newly discovered Amplified Photon Emission Therapy (APET) also comprise part of the product portfolio, but will require longer clinical trials to get to market.
Cancer Therapeutics will be in a position to engage high level personnel and intellectual capital from NanoTherapies to evaluate other synergistic investment opportunities. CTI will then pursue the most promising and valuable technologies to reach the market expeditiously and benefit the lives of cancer patients worldwide.
Cancer Therapeutics Inc is a Delaware corporation. CTI’s Common Stock is listed on the NASD Electronic Bulletin Board under the symbol “CTHP.” The Company’s stock has been traded on the Bulletin Board since March, 2007.
Cancer Therapeutics Inc is located in South Jordan (Salt Lake City), Utah.
Cancer Therapeutics Inc
10757 S. River Front Pkwy.
Suite 125
South Jordan, Utah 84095
Telephone (801) 816-2533
Facsimile (801) 816-2599
Email
Chene Gardner
President, Chief Executive Officer, Chief Financial Officer
John D. Thomas
General Counsel
Outstanding Shares: 85,541,266 as of Sep 07, 2010
The information contained within this iBox including web links, copied information, and any other associated messages/media (hereinafter collectively referred to as "Information") is provided for informational purposes only. The Information should not be construed as investment/trading advice and is not meant to be a solicitation or recommendation to buy, sell, or hold Cancer Therapeutics, Inc. (CTHP) stock.
